JP2014528729A - ウイルスベクター精製システム - Google Patents

ウイルスベクター精製システム Download PDF

Info

Publication number
JP2014528729A
JP2014528729A JP2014533916A JP2014533916A JP2014528729A JP 2014528729 A JP2014528729 A JP 2014528729A JP 2014533916 A JP2014533916 A JP 2014533916A JP 2014533916 A JP2014533916 A JP 2014533916A JP 2014528729 A JP2014528729 A JP 2014528729A
Authority
JP
Japan
Prior art keywords
cell surface
surface marker
ligand
virus
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014533916A
Other languages
English (en)
Japanese (ja)
Inventor
ボヴォレンタ，キアーラ
ストナイユオロ，アンナ
Original Assignee
モルメド エスピーエー
モルメド エスピーエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モルメド エスピーエー, モルメド エスピーエー filed Critical モルメド エスピーエー
Publication of JP2014528729A publication Critical patent/JP2014528729A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014533916A 2011-10-05 2012-10-05 ウイルスベクター精製システム Ceased JP2014528729A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11183937.9 2011-10-05
EP11183937 2011-10-05
PCT/EP2012/069713 WO2013050523A1 (en) 2011-10-05 2012-10-05 Viral vectors purification system

Publications (1)

Publication Number Publication Date
JP2014528729A true JP2014528729A (ja) 2014-10-30

Family

ID=47071247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014533916A Ceased JP2014528729A (ja) 2011-10-05 2012-10-05 ウイルスベクター精製システム

Country Status (13)

Country Link
US (1) US20140248695A1 (https=)
EP (1) EP2764094A1 (https=)
JP (1) JP2014528729A (https=)
KR (1) KR20140068259A (https=)
CN (1) CN103842501B (https=)
AU (1) AU2012320480A1 (https=)
BR (1) BR112014008225A2 (https=)
CA (1) CA2848939A1 (https=)
IL (1) IL231876A0 (https=)
IN (1) IN2014CN03368A (https=)
RU (1) RU2607044C2 (https=)
WO (1) WO2013050523A1 (https=)
ZA (1) ZA201401481B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025197317A1 (ja) * 2024-03-18 2025-09-25 アイポア株式会社 ウイルスベクターの検査方法及び機械学習システム

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2480677T3 (en) 2010-09-02 2015-06-15 Molmed Spa Semi-stable production of lentiviral vectors
GB201310664D0 (en) 2013-06-14 2013-07-31 Mars Inc Feline taste receptors
BR112018070256A2 (pt) 2016-03-31 2019-01-29 Spark Therapeutics, Inc. processo de fabricação de raav totalmente escalável à base de colunas

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503878A (ja) * 2002-10-21 2006-02-02 モルメド スパ 抗原デリバリーシステムとして使用される抗原が形質導入されたｔ細胞
JP2006071437A (ja) * 2004-09-01 2006-03-16 Hjl Inc 血液細胞の新規分類法ならびにそれを利用したテイラーメード治療および予防
JP2007105033A (ja) * 2005-09-13 2007-04-26 Takara Bio Inc レトロウィルス産生用無血清培地

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654183A (en) * 1992-07-27 1997-08-05 California Institute Of Technology Genetically engineered mammalian neural crest stem cells
IT1261847B (it) 1993-09-01 1996-06-03 San Romanello Centro Fond Metodo per marcare cellule eucariote.
EP0781343B1 (de) * 1994-09-08 2003-07-02 Vision 7 GmbH Retrovirale vektorhybride und deren verwendung zum gentransfer
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
EP1284287A4 (en) * 2000-05-10 2004-10-13 Mitsubishi Pharma Corp METHOD FOR PRODUCING A VIRUS VECTOR
IL154987A0 (en) * 2000-09-22 2003-10-31 Virxsys Conditionally replicating viral vectors and their use
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
EP1739180A1 (en) * 2005-06-27 2007-01-03 Max-Delbrück-Centrum für Molekulare Medizin (MDC) T cell line-based packaging cell line for the production of retroviruses by enriching of CD3 expressing cells
WO2011060218A1 (en) * 2009-11-13 2011-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulated programmed death ligand-1
GB0920775D0 (en) * 2009-11-26 2010-01-13 King S College Cells
DK2480677T3 (en) 2010-09-02 2015-06-15 Molmed Spa Semi-stable production of lentiviral vectors
WO2012028680A1 (en) 2010-09-02 2012-03-08 Molmed Spa Semi-stable production of lentiviral vectors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503878A (ja) * 2002-10-21 2006-02-02 モルメド スパ 抗原デリバリーシステムとして使用される抗原が形質導入されたｔ細胞
JP2006071437A (ja) * 2004-09-01 2006-03-16 Hjl Inc 血液細胞の新規分類法ならびにそれを利用したテイラーメード治療および予防
JP2007105033A (ja) * 2005-09-13 2007-04-26 Takara Bio Inc レトロウィルス産生用無血清培地

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YE KAIMING, JOURNAL OF VIROLOGY, vol. V78 N18, JPN6016029301, September 2004 (2004-09-01), pages 9820 - 9827, ISSN: 0003370005 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025197317A1 (ja) * 2024-03-18 2025-09-25 アイポア株式会社 ウイルスベクターの検査方法及び機械学習システム

Also Published As

Publication number Publication date
US20140248695A1 (en) 2014-09-04
CN103842501B (zh) 2017-12-08
IL231876A0 (en) 2014-05-28
AU2012320480A1 (en) 2014-04-24
WO2013050523A1 (en) 2013-04-11
RU2014117466A (ru) 2015-11-10
KR20140068259A (ko) 2014-06-05
ZA201401481B (en) 2015-04-29
IN2014CN03368A (https=) 2015-07-03
EP2764094A1 (en) 2014-08-13
RU2607044C2 (ru) 2017-01-10
NZ623092A (en) 2016-07-29
BR112014008225A2 (pt) 2017-04-11
CA2848939A1 (en) 2013-04-11
CN103842501A (zh) 2014-06-04

Similar Documents

Publication Publication Date Title
RU2761555C2 (ru) Способы, наборы, средства и устройства для трансдукции
JP2026026312A (ja) レトロウイルスおよびレンチウイルスベクター
JP7262465B2 (ja) Ｎｋ細胞形質導入のための方法
EP3445774B1 (en) Stable pseudotyped lentiviral particles and uses thereof
AU2022218478B2 (en) Bio-production of lentiviral vectors
EP3186382B1 (en) Method and means for purifying retroviral vectors
CN116063574A (zh) 靶向her2的嵌合抗原受体
US20140057354A1 (en) Antigen-specific regulatory t-cell induction
CN116157116A (zh) 用于产生病毒融合体的方法和组合物
CN103842501B (zh) 病毒载体纯化系统
Coroadinha Cancer gene therapy: development and production of lentiviral vectors for gene therapy
CN104212766B (zh) 一种骨髓间充质干细胞及其用途
CN115707485A (zh) 靶向Her-2 CAR-NK应用于肿瘤治疗的方法
NZ623092B2 (en) Viral vectors purification system
WO2024226858A1 (en) Methods for viral vector manufacturing
US20260022352A1 (en) Compositions and methods for purifying lentivirus particles
CN117867028A (zh) 慢病毒包装系统

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180206

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20180626